Latest news
Diversity in the OR: 3 barrier-breaking female surgeons share their stories
Only one in 10 orthopedic surgeons in the U.S. are women. Learn how Johnson & Johnson is working to change that stat.
How Johnson & Johnson is fighting medical counterfeiting
Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
Photo courtesy of GBP LATAM team
More from Johnson & Johnson
What are cataracts?
If you can’t read a screen without jacking up the brightness level or if night driving leaves you seeing fuzzy halos around traffic lights, you may among the 20 million U.S. adults who develops a cataract—the most common cause of vision loss worldwide. Luckily a simple surgical procedure can have you viewing the world in crisp, bright color again. Here’s what to know about cataract symptoms and removal.
Meet two brothers who are revolutionizing the way scientists develop treatments for cancer
Justin and Colin Farlow share how their next-generation cell and gene therapies are helping Johnson & Johnson in its quest to get in front of cancer.
What to know about We All Belong: 2023 DEI Impact Review
The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.
4 things to know about Johnson & Johnson’s 2023 Health for Humanity Report
The annual report details the company’s ongoing work in helping to create a healthier world, building a more diverse and inclusive workforce, championing global health equity and more.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.
Press releases
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive
Shockwave Medical Expands U.S. Peripheral IVL Portfolio with Enhanced Catheter
Shockwave E8 Augments IVL’s Capabilities for Physicians Treating Peripheral Arterial Disease Above and Below the Knee
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5 TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis
